Business Wire

MA-BOARD-INTERNATIONAL

8.9.2021 16:02:19 CEST | Business Wire | Press release

Share
Board International Appoints Marco Limena as Chief Executive Officer

Board International, the #1 Decision-Making Platform provider, today announced the appointment of Marco Limena as Chief Executive Officer. Limena will focus on expanding the rapid growth of the company while leading its next phase of development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005775/en/

“We are excited to welcome Marco as the new CEO of Board International. Marco is a leader who has contributed to the growth and transformation of many technology firms. Over his career, he has earned a reputation as a strategic executive, and we have tremendous confidence he will be an exceptional leader.” stated Fredrik Näslund, Partner and Head of Technology & Payments, Nordic Capital Advisors and Board Director at Board International.

“I am honored to join Board International as the company is positioned at the forefront of a critical and fast-growing market opportunity. The rapid pace of change has created an imperative for companies to reconfigure their operations and an opportunity to transform them. Board’s unique capability to unify planning and analytics and bust planning and data silos across the organization can really play a pivotal role in transforming decision-making processes in every business,” said Limena. “I am excited to join a very talented organization which, with its partner ecosystem, is fully dedicated to helping customers innovate and succeed.”

During his international career, Limena has worked in both leading technology corporations and growth-oriented B2B software businesses.

At Microsoft, Mr. Limena was Vice President of Hosting & Cloud Providers, responsible for the global B2B commercial operations of the company’s cloud software and services through the partner ecosystem. Prior to Microsoft, Marco Limena spent 14 years at HP, during which time he held several corporate roles in Palo Alto, including Vice President of HP’s telecoms solutions business.

Marco has extensive experience working with leading Private Equity firms in multiple CEO assignments in B2B software businesses, and as a Board Director in private and public companies.

“Marco is a proven technology leader and will drive the solid execution of Board’s strategy to take advantage of the many opportunities ahead, as the relevance of planning and analytics in driving enterprises’ performance continues to increase,” commented Maurizio Carli, Chairman of the company.

About Board

Board is the #1 Decision-Making Platform. Board’s solutions enable people to have a transformative impact on their business, helping them to intuitively explore and leverage their data in a flexible, all-in-one Decision-Making Platform. By unifying business Intelligence, planning, and predictive analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, more than 3,000 organizations worldwide, including H&M, Toyota, Coca-Cola, KPMG, Puma, and Sony have deployed end-to-end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com

Link:

ClickThru

Social Media:

https://www.facebook.com/BOARD.International/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye